These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

472 related articles for article (PubMed ID: 24351397)

  • 1. Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials.
    Valle JW; Furuse J; Jitlal M; Beare S; Mizuno N; Wasan H; Bridgewater J; Okusaka T
    Ann Oncol; 2014 Feb; 25(2):391-8. PubMed ID: 24351397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fluoropyrimidines plus cisplatin versus gemcitabine/gemcitabine plus cisplatin in locally advanced and metastatic biliary tract carcinoma - a retrospective study.
    Croitoru A; Gramaticu I; Dinu I; Gheorghe L; Alexandrescu S; Buica F; Luca I; Becheanu G; Herlea V; Simionov I; Hrehoret D; Lupescu I; Popescu I; Diculescu M
    J Gastrointestin Liver Dis; 2012 Sep; 21(3):277-84. PubMed ID: 23012669
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cisplatin and gemcitabine in patients with advanced biliary tract cancer (ABC) and persistent jaundice despite optimal stenting: Effective intervention in patients with luminal disease.
    Lamarca A; Benafif S; Ross P; Bridgewater J; Valle JW
    Eur J Cancer; 2015 Sep; 51(13):1694-703. PubMed ID: 26066735
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lenvatinib Plus Programmed Cell Death Protein-1 Inhibitor Beyond First-Line Systemic Therapy in Refractory Advanced Biliary Tract Cancer: A Real-World Retrospective Study in China.
    Shi C; Li Y; Yang C; Qiao L; Tang L; Zheng Y; Chen X; Qian Y; Yang J; Wu D; Xie F
    Front Immunol; 2022; 13():946861. PubMed ID: 35967452
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognosis and prognostic factors in patients with advanced biliary tract cancer depending on its anatomical location.
    Song BG; Park JK; Kim HS; Kim K; Park JK; Lee KH; Lee KT; Lee JK
    Scand J Gastroenterol; 2019 Jun; 54(6):740-745. PubMed ID: 31136212
    [No Abstract]   [Full Text] [Related]  

  • 6. Gemcitabine-based chemotherapy for advanced biliary tract carcinomas.
    Abdel-Rahman O; Elsayed Z; Elhalawani H
    Cochrane Database Syst Rev; 2018 Apr; 4(4):CD011746. PubMed ID: 29624208
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advanced biliary tract carcinomas: a retrospective multicenter analysis of first and second-line chemotherapy.
    Fiteni F; Jary M; Monnien F; Nguyen T; Beohou E; Demarchi M; Dobi E; Fein F; Cleau D; Fratté S; Nerich V; Bonnetain F; Pivot X; Borg C; Kim S
    BMC Gastroenterol; 2014 Aug; 14():143. PubMed ID: 25117717
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Derived neutrophil lymphocyte ratio may predict benefit from cisplatin in the advanced biliary cancer: the ABC-02 and BT-22 studies.
    Grenader T; Nash S; Plotkin Y; Furuse J; Mizuno N; Okusaka T; Wasan H; Valle J; Bridgewater J
    Ann Oncol; 2015 Sep; 26(9):1910-1916. PubMed ID: 26037798
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Translating the ABC-02 trial into daily practice: outcome of palliative treatment in patients with unresectable biliary tract cancer treated with gemcitabine and cisplatin.
    Dierks J; Gaspersz MP; Belkouz A; van Vugt JLA; Coelen RJS; de Groot JWB; Ten Tije AJ; Meijer WG; Pruijt JFM; van Voorthuizen T; van Spronsen DJ; Rentinck M; Ten Oever D; Smit JM; Otten HM; van Gulik TM; Wilmink JW; Groot Koerkamp B; Klümpen H
    Acta Oncol; 2018 Jun; 57(6):807-812. PubMed ID: 29265948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors in patients with advanced biliary tract cancer treated with first-line gemcitabine plus cisplatin: retrospective analysis of 740 patients.
    Kim BJ; Hyung J; Yoo C; Kim KP; Park SJ; Lee SS; Park DH; Song TJ; Seo DW; Lee SK; Kim MH; Park JH; Cho H; Ryoo BY; Chang HM
    Cancer Chemother Pharmacol; 2017 Jul; 80(1):209-215. PubMed ID: 28597043
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nab-Paclitaxel and Gemcitabine as First-line Treatment of Advanced or Metastatic Cholangiocarcinoma: A Phase 2 Clinical Trial.
    Sahai V; Catalano PJ; Zalupski MM; Lubner SJ; Menge MR; Nimeiri HS; Munshi HG; Benson AB; O'Dwyer PJ
    JAMA Oncol; 2018 Dec; 4(12):1707-1712. PubMed ID: 30178032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A phase 1b study of Selumetinib in combination with Cisplatin and Gemcitabine in advanced or metastatic biliary tract cancer: the ABC-04 study.
    Bridgewater J; Lopes A; Beare S; Duggan M; Lee D; Ricamara M; McEntee D; Sukumaran A; Wasan H; Valle JW
    BMC Cancer; 2016 Feb; 16():153. PubMed ID: 26912134
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic Factors for Survival in Patients with Advanced Intrahepatic Cholangiocarcinoma Treated with Gemcitabine plus Cisplatin as First-Line Treatment.
    Ishimoto U; Kondo S; Ohba A; Sasaki M; Sakamoto Y; Morizane C; Ueno H; Okusaka T
    Oncology; 2018; 94(2):72-78. PubMed ID: 29017161
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gemcitabine plus sorafenib versus gemcitabine alone in advanced biliary tract cancer: a double-blind placebo-controlled multicentre phase II AIO study with biomarker and serum programme.
    Moehler M; Maderer A; Schimanski C; Kanzler S; Denzer U; Kolligs FT; Ebert MP; Distelrath A; Geissler M; Trojan J; Schütz M; Berie L; Sauvigny C; Lammert F; Lohse A; Dollinger MM; Lindig U; Duerr EM; Lubomierski N; Zimmermann S; Wachtlin D; Kaiser AK; Schadmand-Fischer S; Galle PR; Woerns M;
    Eur J Cancer; 2014 Dec; 50(18):3125-35. PubMed ID: 25446376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase 2 study of copanlisib in combination with gemcitabine and cisplatin in advanced biliary tract cancers.
    Tan ES; Cao B; Kim J; Al-Toubah TE; Mehta R; Centeno BA; Kim RD
    Cancer; 2021 Apr; 127(8):1293-1300. PubMed ID: 33289918
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Panitumumab in combination with gemcitabine and oxaliplatin does not prolong survival in wild-type KRAS advanced biliary tract cancer: A randomized phase 2 trial (Vecti-BIL study).
    Leone F; Marino D; Cereda S; Filippi R; Belli C; Spadi R; Nasti G; Montano M; Amatu A; Aprile G; Cagnazzo C; Fasola G; Siena S; Ciuffreda L; Reni M; Aglietta M
    Cancer; 2016 Feb; 122(4):574-81. PubMed ID: 26540314
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial.
    Malka D; Cervera P; Foulon S; Trarbach T; de la Fouchardière C; Boucher E; Fartoux L; Faivre S; Blanc JF; Viret F; Assenat E; Seufferlein T; Herrmann T; Grenier J; Hammel P; Dollinger M; André T; Hahn P; Heinemann V; Rousseau V; Ducreux M; Pignon JP; Wendum D; Rosmorduc O; Greten TF;
    Lancet Oncol; 2014 Jul; 15(8):819-28. PubMed ID: 24852116
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Individual patient data meta-analysis of adjuvant gemcitabine-based chemotherapy for biliary tract cancer: combined analysis of the BCAT and PRODIGE-12 studies.
    Edeline J; Hirano S; Bertaut A; Konishi M; Benabdelghani M; Uesaka K; Watelet J; Ohtsuka M; Hammel P; Kaneoka Y; Joly JP; Yamamoto M; Monard L; Ambo Y; Louvet C; Ando M; Malka D; Nagino M; Phelip JM; Ebata T
    Eur J Cancer; 2022 Mar; 164():80-87. PubMed ID: 35182925
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Landmark survival analysis and impact of anatomic site of origin in prospective clinical trials of biliary tract cancer.
    McNamara MG; Lopes A; Wasan H; Malka D; Goldstein D; Shannon J; Okusaka T; Knox JJ; Wagner AD; André T; Cunningham D; Moehler M; Jensen LH; Koeberle D; Bekaii-Saab T; Bridgewater J; Valle JW
    J Hepatol; 2020 Nov; 73(5):1109-1117. PubMed ID: 32446715
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase-II study of gemcitabine and cisplatin in patients with metastatic biliary and gallbladder cancer.
    Meyerhardt JA; Zhu AX; Stuart K; Ryan DP; Blaszkowsky L; Lehman N; Earle CC; Kulke MH; Bhargava P; Fuchs CS
    Dig Dis Sci; 2008 Feb; 53(2):564-70. PubMed ID: 17597402
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.